The effect of Dexmedetomidine intravenous infusion on reducing the pain of normal vaginal delivery.

Evaluation of the effect of Dexmedetomidine's intravenous infusion on the reduction of vaginal delivery pain in nulipar and full-term women

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161022030421N5

Enrollment

Registered

2019-07-20

Start date

2019-02-20

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal delivery. Pain, not elsewhere classified

Interventions

Intervention 1: Intervention group: after the onset of the active phase of labor, the initial dose (1 µg / kg ) of intravenous Dexmedetomidine (Manufacturing of Exir Pharmaceutical Company) will be in

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: All nulli para pregnant women Full term Class 1 and 2 American Society of Anesthesiologist Candidate for vaginal delivery

Exclusion criteria

Exclusion criteria: Patients with liver failure renal failure grade 2 or 3 heart block history of neurological and psychiatric illness drug addicts

Design outcomes

Primary

Measure	Time frame
Change in severity of labor pain. Timepoint: After the onset of the active phase of labor, and commencing the onset of the dexmedotomidine drug, the patient will be examined for pain intensity every 5 minutes until the placenta is removed and the episiotomy is repaired. Method of measurement: Pain Evaluation by visual analogue scale score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Lak

Bagheiat-allah University of Medical Sciences

marziehlak@bmsu.ac.Ir+98 21 2244 9013

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026